Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

India flag India · Delayed Price · Currency is INR
135.00
-2.26 (-1.65%)
Mar 6, 2026, 3:29 PM IST
38.11%
Market Cap 11.87B
Revenue (ttm) 5.94B
Net Income (ttm) 2.49B
Shares Out 86.71M
EPS (ttm) 31.33
PE Ratio 4.37
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 341,034
Average Volume 1,277,988
Open 136.01
Previous Close 137.26
Day's Range 134.40 - 140.98
52-Week Range 68.72 - 151.98
Beta 0.64
RSI 53.99
Earnings Date May 26, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance... [Read more]

Sector Healthcare
Founded 1995
Employees 1,246
Stock Exchange National Stock Exchange of India
Ticker Symbol INDSWFTLAB
Full Company Profile

Financial Performance

In fiscal year 2025, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -67.13% compared to the previous year's 17.09 billion. Earnings were 2.50 billion, a decrease of -53.51%.

Financial Statements

News

Ind-Swift Laboratories steps up export push with Rs 40 crore Jammu facility upgrade

Ind-Swift Laboratories Limited has approved a capital investment of approximately ₹400 million (around ₹40 crore) to upgrade its finished dosage...

19 days ago - Business Upturn